

The role of cancer patients in HTA & disinvestment: Recommendations from ECPC and CanCon

Value of Innovation in Oncology WWW.ECPC.ORG/INNOVATION

- **What is it?**
ECPC's vision for the future of oncology
- **What it recommends?**
 - Harmonise HTA evaluation at EU level
 - Establishment of an **EU-wide HTA body (agency)**
 - **Unique, pan-European relative effectiveness assessment**, based on EUnetHTA Core Model
 - **Patients MUST be formally and routinely included in HTA evaluation**
- **ECPC actions**
 - Comments to the **Commission's consultation on HTA harmonization**
 - Providing input to the Commission in view of the **legislative proposal (end of 2017)**
 - Lobbying to the European Parliament/Council
 - **Providing info to ECPC Members**
 - **Collaboration with EUnetHTA3 and HTA Network**

Joint Action on Cancer Control WWW.CANCERCONTROL.EU

- **What is it?**
 - The most important EU initiative on cancer control
 - Objective: define how to design and implement national cancer plans
 - **Partners: 17 EU ministries + patients/HCPs**
- **What it recommends?**
 - Cancer care IS multidisciplinary: to ensure sustainability governments must evaluate all interventions, not just medicines
 - HTA is a key tool to implement disinvestment policies
 - Expert patients and advocates must be involved in the design and implementation of disinvestment strategies.
 - **Patients' education: increasing patients' familiarity with HTA is a pre-requisite for ensuring that patients can meaningfully contribute to the debate on disinvestment.**
- **What 's next?**
 - CanCon recommendations are not binding!
 - ECPC is promoting implementation at national level